ClinConnect ClinConnect Logo
Search / Trial NCT06224114

Coloured-light in Retinitis Pigmentosa.

Launched by UNIVERSITY COLLEGE, LONDON · Jan 24, 2024

Trial Information

Current as of July 03, 2025

Not yet recruiting

Keywords

Inherited Eye Disease Retinal Dystrophy Retinitis Pigmentosa Visual Impairment Photobiomodulation Mitochondrial Dysfunction

ClinConnect Summary

This clinical trial is exploring how different colors of light can affect color vision in adults with a condition called retinitis pigmentosa (RP), which affects how well people can see. If you are over 18 years old and have been genetically diagnosed with RP, you might be eligible to participate. To qualify, you should have a certain level of vision and specific eye structures that are still intact.

During the study, participants will have their vision tested at the beginning and end of the trial. You will randomly receive one of two colored-light torches to use at home for three minutes each morning for 28 days. This means you won’t know which color you are using, and neither will the study team. The trial aims to see if using these colored lights can improve color vision in people with RP. The study is not yet recruiting participants, but it’s an exciting opportunity to help researchers learn more about how light can impact vision in this condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Over 18 years old
  • Typical RP where the underlying genetic cause is known. This may include PRPF31, PRPF8, SNRNP200, RHO, RP1 \[autosomal dominant\] and USH2A, EYS \[autosomal recessive\]
  • VA of 0.30 LogMAR (6/12) or better in the study eye
  • Preserved foveal structure defined by intact outer retinal (ellipsoid zone) at the fovea on Optical Coherence Tomography (OCT) and a hyperfluorescent ring within the temporal vascular arcades on Fundus Autofluorescence (FAF) in the study eye
  • Willing and able to provide written informed consent
  • Exclusion Criteria:
  • Co-existing ocular pathology will be excluded; however, participants with macular oedema, a common pre-symptomatic manifestation of foveal involvement, will not be excluded
  • Concurrent and/or recent involvement in other research that is likely to interfere with the intervention within 6 months of study enrolment
  • Unwilling or able to provide written informed consent.

About University College, London

University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.

Locations

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Hannah Dunbar, PhD

Principal Investigator

UCL Institute of Ophthalmology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported